Controller

Job Opening for Research Associate

 

Applied Genetic Technologies Corporation, AGTC, is a privately-held clinical stage biotechnology company developing novel systems to deliver human therapeutics. Founded in Gainesville, FL,
the company has successfully entered clinical testing for their 2 lead programs and has received over $43 million in private equity funding, the most recent round of $11.8M from blue-chip investors InterWest, Intersouth and MedImmune Ventures.

Qualifications:

• BA or Masters Degree in Accounting, or related discipline
• Minimum of 5 years upper level accounting experience as well as supervisory experience. Experience in Biotechnology or related industry a plus.
• The candidate must have excellent communication skills, both oral and written.

Job Description:

 

AGTC is looking for an experienced Controller. In addition to duties typical of this position the Controller will oversee the Human Resources function and assist the CEO with a wide variety of projects in accounting, finance and contracts. There will also be opportunities to work on
teams in business development and marketing. This position reports directly to the CEO and the Accounting Manager reports to the Controller.

AGTC offers competitive salaries based on experience, with a full range of company paid benefits. In addition, AGTC will provide $4,000 toward the qualified candidate’s relocation expenses. EOE. AGTC maintains a drug free workplace.
 

Please send CV or resume to: Teresa Heal, Applied Genetic Technologies Corporation, 11801 Research Drive, STE D, Alachua, FL32615, theal@agtc.com

 

More about AGTC:

The Company demonstrated initial clinical proof of concept when its lead indication, for treatment of Alpha-1 Antitrypsin Deficiency (Alpha 1 an inherited form of emphysema), completed enrollment with
a positive safety profile and evidence of sustained protein expression. The Phase II trial began in 2010 and is designed as a dose escalation trial to obtain sustained and efficacious levels of protein expression. AGTC’s ophthalmology focus began in 2004 with an agreement to develop therapies for
Wet Age-Related Macular Degeneration with Genzyme; a Phase I trial is currently underway. AGTC’s independent ocular program for the treatment of Leber’s Congenital Amaurosis (LCA) recently demonstrated safety and clinical proof of concept with sustained expression of RPE65 in the clinic and a Phase II trial began in 2009. AGTC augmented their ophthalmology portfolio by initiating
preclinical testing of treatments for two genetic forms of retinal degeneration. The Company has a strong intellectual property position; its patents protect not only the therapeutic delivery system, but also specific product compositions, genes, delivery methods and proprietary, commercial-scale
production methods. AGTC’s mission is to combine this portfolio with unmatched scientific and clinical expertise to create and bring new healthcare products to the ophthalmology market.